Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt executed a large cluster of open-market sales totaling ~$6.7M over Sept 10-11, 2026, following a $ | Sep 15, 2026 |
| CORT | CLUSTER | bearish | 4/10 | Two Corcept Therapeutics insiders sold a combined $1.64M in open-market sales over two days, with no indication of 10b5- | Sep 15, 2026 |
| GILD | CLUSTER | neutral | 3/10 | Two GILD executives (CFO Dickinson and CCO Mercier) sold a combined $523K in open-market sales on September 15, 2026, wh | Sep 15, 2026 |
| CORT | CLUSTER | bearish | 4/10 | Two Corcept Therapeutics insiders (a director and a senior officer) sold a combined $1.64M in open-market sales over a 3 | Sep 15, 2026 |
| GILD | CLUSTER | neutral | 2/10 | Gilead Sciences CFO and Chief Communications Officer executed open-market sales totaling $523K on September 15, 2026, fo | Sep 15, 2026 |
| ORKA | CLUSTER | neutral | 3/10 | Three Oruka insiders (CEO, COO, SVP Finance) sold a combined $375,574.92 in open-market sales on 2026-09-15. The cluster | Sep 15, 2026 |
| NBIX | CLUSTER | neutral | 3/10 | Insider cluster shows 2 insiders with open-market sales totaling $493K (CFO Abernethy sold 2,311 shares for $363K; anoth | Sep 15, 2026 |
| VNRX | 8-K | bearish | 5/10 | VolitionRx Limited (VNRX) filed an 8-K under Item 3.02 to disclose an unregistered sale of equity securities, indicating | Sep 15, 2026 |
| FTH | 3 | neutral | 2/10 | Karen H. Vousden filed an initial statement of beneficial ownership (Form 3) with the SEC, reporting 42,631 shares of Fa | Sep 15, 2026 |
| KRRO | CLUSTER | neutral | 2/10 | Insider cluster: 2 insiders sold a total of $450K in KRRO over the past 7 days. The most recent transaction is a single | Sep 15, 2026 |
| INBX | 144 | neutral | 2/10 | No summary provided | Sep 15, 2026 |
| PHVS | CLUSTER | bearish | 5/10 | Four Pharvaris insiders, including the CEO and President, sold a total of $2.15M in open-market shares over a 7-day wind | Sep 15, 2026 |
| AVXL | DFAN14A | bullish | 7/10 | PVG Asset Management, holding 337,663 shares (~0.14% of AVXL), filed definitive additional proxy soliciting materials on | Sep 15, 2026 |
| JAGX | 8-K | bearish | 7/10 | Jaguar Health issued approximately 3.4 million new common shares across multiple debt-for-equity and preferred-for-equit | Sep 15, 2026 |
| ABEO | 8-K | neutral | 2/10 | Abeona Therapeutics filed an 8-K furnishing an updated investor presentation for the H.C. Wainwright 28th Annual Global | Sep 15, 2026 |
| BETRF | 6-K | neutral | 4/10 | BetterLife Pharma filed its Notice of Annual General Meeting and Information Circular for the October 14, 2026 meeting. | Sep 15, 2026 |
| VERA | 8-K | bullish | 8/10 | Vera Therapeutics announced that TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis | Sep 15, 2026 |
| BLSM | 8-K | neutral | 3/10 | BlossomHill Therapeutics filed an 8-K with Item 7.01 (Regulation FD Disclosure) and Item 9.01 (exhibits), but the docume | Sep 15, 2026 |
| ZEOX | 8-K | neutral | 2/10 | ZEO ScientifiX filed an 8-K announcing its planned expansion into Georgia and Tennessee following the enactment of new s | Sep 15, 2026 |
| LEGN | 6-K | neutral | 3/10 | Legend Biotech appointed Ingrid Zhang as permanent CEO, effective September 15, 2026, succeeding interim CEO Alan Bash w | Sep 15, 2026 |
| QNTM | 6-K | neutral | 2/10 | Quantum Biopharma Ltd. filed a Form 6-K with the SEC. The document content was unavailable for analysis, so the filing's | Sep 15, 2026 |
| LBRX | 8-K | neutral | 3/10 | LB Pharmaceuticals Inc. filed an 8-K covering Item 5.02 (officer/director departure or appointment), Item 7.01 (Regulati | Sep 15, 2026 |
| SAFX | 8-K | bearish | 8/10 | XCF Global entered into an at-the-market (ATM) sales agreement with Roth Capital and H.C. Wainwright to sell up to $100M | Sep 15, 2026 |
| AZN | 6-K | neutral | 2/10 | AstraZeneca's Non-Executive Chair Michel Demaré purchased 2,500 ordinary shares at £121.21 per share on 14 September 202 | Sep 15, 2026 |
| COYA | 8-K | neutral | 4/10 | Coya Therapeutics announced that the 100th patient has been enrolled in its Phase 2/3 ALSTARS trial (COYA 302 for ALS), | Sep 15, 2026 |
| JAZZ | 8-K | bullish | 6/10 | Jazz Pharmaceuticals completed the acquisition of Actio Biosciences for $820 million upfront, adding ABS-1230, a clinica | Sep 15, 2026 |
| BDRX | 6-K | mixed | 6/10 | Biodexa Pharmaceuticals entered into a warrant inducement agreement on September 14, 2026, with an existing accredited i | Sep 15, 2026 |
| PLSE | 8-K | bullish | 6/10 | Pulse Biosciences announced completion of patient enrollment (100 patients, doubled from original 50) in its PRECISE-BTN | Sep 15, 2026 |
| EVMN | 8-K | neutral | 4/10 | Evommune posted an updated corporate presentation on its website via an 8-K (Item 7.01). The presentation highlights Pha | Sep 15, 2026 |
| SRRK | 8-K | neutral | 3/10 | Scholar Rock filed an 8-K to correct an error made during the September 14 investor call announcing FDA approval of ISEM | Sep 15, 2026 |